BioMérieux Buys ARGENE for $54M to Boost Virology-Testing Play

The buy, which could be worth an additional $7.2 million in contingent payments, is also meant to enable it to "accelerate the time to market" of a broad test menu on the new molecular-test platform it is developing with Biocartis.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.